OlympiAD试验:奥拉帕利对比化疗在gBRCA突变/HER2阴性转移性乳腺癌中的患者报告结局
III期OlympiAD研究显示,在gBRCA突变且HER2阴性的转移性乳腺癌患者中,奥拉帕利单药对比医生选择的化疗(TPC)可显著改善无进展生存期。本文报告健康相关生活质量(HRQoL)结果:奥拉帕利组整体健康状况/生活质量评分较基线平均变化为3.9,TPC组为-3.6,组间差异7.5分(95%CI 2.48-12.44;P=0.0035),奥拉帕利组生活质量恶化时间未达到,TPC组为15.3个月(HR 0.44,95%CI 0.25-0.77;P=0.004)。
要点
- 奥拉帕利组整体健康状况/生活质量较基线改善,TPC组恶化,组间差异有统计学意义。
- 奥拉帕利组生活质量恶化时间未达到,TPC组为15.3个月,HR 0.44。
- 仅恶心/呕吐症状评分在奥拉帕利组较TPC组更差。
核心结论
- 与化疗TPC相比,奥拉帕利治疗gBRCA突变/HER2阴性转移性乳腺癌患者可持续改善健康相关生活质量。
研究设计与样本
- III期OlympiAD研究(NCT02000622),患者按2:1随机接受奥拉帕利单药(300 mg每日两次)或单药TPC。
- 主要HRQoL终点为EORTC QLQ-C30两项整体健康状况/生活质量评分较基线的平均变化,采用重复测量混合模型评估。
主要发现
- 问卷总体依从率:奥拉帕利组93.2%,TPC组76.3%。
- 整体健康状况/生活质量组间比较:奥拉帕利组平均变化3.9(标准差1.2),TPC组-3.6(标准差2.2),差异7.5分(95%CI 2.48-12.44;P=0.0035)。
- 整体健康状况/生活质量最佳总体反应为「改善」的患者比例:奥拉帕利组33.7%,TPC组13.4%。
- 整体健康状况/生活质量恶化中位时间:奥拉帕利组未达到,TPC组15.3个月(HR 0.44;95%CI 0.25-0.77;P=0.004)。
- EORTC QLQ-C30症状和功能子量表中,仅恶心/呕吐症状评分在奥拉帕利组较TPC组更差(所有访视对比基线)。
临床怎么用
- 对于gBRCA突变/HER2阴性转移性乳腺癌患者,奥拉帕利在改善无进展生存期的同时可维持或改善生活质量。
- 临床决策时可参考患者报告结局,奥拉帕利组整体健康状况/生活质量优于化疗TPC。
- 需关注奥拉帕利治疗相关的恶心/呕吐症状,并进行相应管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase III OlympiAD study (NCT02000622) showed a statistically significant progression-free survival benefit with olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA mutation and human epidermal growth factor receptor 2-negative metastatic breast cancer. From this study, we report the effect of olaparib on health-related quality of life (HRQoL). METHODS: Patients were randomised 2:1 to olaparib monotherapy (300 mg twice daily) or single-agent TPC. The primary HRQoL end-point was mean change from baseline in the two-item global health status/QoL score determined from patient-completed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module (EORTC QLQ-C30) questionnaires and assessed using a mixed model for repeated measures. Symptoms and functioning domains, best overall response and time to deterioration of QoL were also evaluated. RESULTS: Overall questionnaire compliance rates were 93.2% for olaparib and 76.3% for TPC. Between-treatment global health status/QoL comparison showed a significant improvement in the olaparib arm versus the TPC arm, with mean change of 3.9 (standard deviation 1.2) versus -3.6 (2.2), a difference of 7.5 points (95% confidence interval [CI]: 2.48, 12.44; P = 0.0035). A higher proportion of patients in the olaparib arm showed a best overall response of 'improvement' in global health status/QoL (33.7% vs 13.4%). Median time to global health status/QoL deterioration was not reached in olaparib patients and was 15.3 months for TPC patients (hazard ratio: 0.44 [95% CI: 0.25, 0.77]; P = 0.004). For EORTC QLQ-C30 symptoms and functioning subscales, only nausea/vomiting symptom score was worse in the olaparib arm than in the TPC arm (across all visits compared with baseline). CONCLUSION: HRQoL was consistently improved for patients treated with olaparib, compared with chemotherapy TPC.
引用
- Robson M, Ruddy KJ, Im SA, et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer. 2019. PMID: 31446213. doi:10.1016/j.ejca.2019.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。